Press release
May 11, 2026
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Aktis Oncology, Inc. (AKTS)
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segments Initiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027 Announced AKY-2519 clinical imaging and dosimetry